Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Icecure Medical ( (ICCM) ) has issued an update.
IceCure Medical participated in the 2025 Society of Interventional Oncology Annual Meeting, highlighting their ProSense® cryoablation system through award-winning studies and hands-on training sessions for breast cancer treatment. The company anticipates the FDA’s market authorization decision in Q1 2025, which could significantly impact their market positioning and adoption, especially in the U.S. where interest among medical professionals is growing.
More about Icecure Medical
IceCure Medical, listed on Nasdaq as ICCM, specializes in developing and marketing advanced cryoablation therapy systems using liquid nitrogen to destroy tumors. Their primary focus is on breast, kidney, bone, and lung cancer. The minimally invasive technology offers a safe alternative to surgical tumor removal and is marketed globally with approvals in the U.S., Europe, and China.
YTD Price Performance: 1.63%
Average Trading Volume: 643,967
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $70.71M
For an in-depth examination of ICCM stock, go to TipRanks’ Stock Analysis page.
